Patents by Inventor Masakazu HOMMA

Masakazu HOMMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210108207
    Abstract: The present invention provides, for example, an oligonucleotide derivative or a salt thereof comprising a circular oligonucleotide and a linear oligonucleotide, wherein the circular oligonucleotide and the linear oligonucleotide have base sequences complementary to each other, and form a complex via a hydrogen bond between the complementary base sequences, and a method for producing the same.
    Type: Application
    Filed: May 1, 2018
    Publication date: April 15, 2021
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Junichiro YAMAMOTO, Fumikazu SHINOHARA, Toshimasa HARUMOTO, Masakazu HOMMA, Kenji HAGIWARA
  • Publication number: 20210107997
    Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 15, 2021
    Applicants: RIKEN, KYOWA KIRIN CO., LTD.
    Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
  • Patent number: 10906990
    Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: February 2, 2021
    Assignees: RIKEN, KYOWA KIRIN CO., LTD.
    Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
  • Patent number: 10745700
    Abstract: The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: August 18, 2020
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Keiji Uehara, Yasuhiro Suzuki, Hiroto Iwai, Masakazu Homma, Yuichi Fukuda, Tatsuto Kiuchi
  • Publication number: 20190127488
    Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.
    Type: Application
    Filed: August 18, 2016
    Publication date: May 2, 2019
    Applicants: RIKEN, KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kensaku SAKAMOTO, Kazumasa OHTAKE, Yoshimi YAMAGUCHI, Shigeyuki YOKOYAMA, Tatsuo YANAGISAWA, Akiko MATSUMOTO, Akifumi KATO, Yasuhisa SHIRAISHI, Kaname KIMURA, Masakazu HOMMA
  • Publication number: 20190055558
    Abstract: The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.
    Type: Application
    Filed: January 30, 2017
    Publication date: February 21, 2019
    Applicant: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Keiji UEHARA, Yasuhiro SUZUKI, Hiroto IWAI, Masakazu HOMMA, Yuichi FUKUDA, Tatsuto KIUCHI
  • Patent number: 9701689
    Abstract: The present invention provides a heterocyclic compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, in which XA, R1, YA, R2, R3A, and R4A are as defined herein. The compound of formula (I) inhibits a C-C chemokine receptor type 10 (CCR10) receptor and is useful as a prophylactic and/or therapeutic agent for skin diseases.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: July 11, 2017
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenji Uchida, Toshimi Kanai, Masakazu Homma, Seiji Aratake, Tatsuya Ishimori
  • Publication number: 20150299214
    Abstract: The present invention provides a heterocyclic compound represented by the following formula (I), wherein XA represents CH and the like, R1 represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, YA represents —NH— and the like, R2 represents a hydrogen atom and the like, R3A represents the following formula (R3A-1) (wherein, R3 represents hydroxy and the like) and the like, and R4A represents the following formula (R4A-1) (wherein, R4 and R5 are the same or different and each represents a hydrogen atom and the like) and the like, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.
    Type: Application
    Filed: November 29, 2013
    Publication date: October 22, 2015
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenji UCHIDA, Toshimi KANAI, Masakazu HOMMA, Seiji ARATAKE, Tatsuya ISHIMORI